LONDON--(BUSINESS WIRE)--GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an ...

GlaxoSmithKline’s Nucala has suffered against a more convenient AstraZeneca rival, but the company finally has an answer. Thursday, the FDA greenlighted two new delivery options for Nucala: an ...

The US Food and Drug Administration (FDA) has approved two new methods for administering mepolizumab (Nucala, GlaxoSmithKline), an autoinjector and a prefilled safety syringe, which patients or ...

In its heated severe asthma fight with AstraZeneca’s Fasenra, GlaxoSmithKline could take solace in the fact that its drug was more convenient for patients, with a self-administered injection option.

Previously, the treatment had only been available as a lyophilized powder for reconstitution that required administration by a healthcare professional. The Food and Drug Administration has approved ...

Nucala (mepolizumab) is typically a long-term treatment that’s injected every 4 weeks. The decision to continue taking Nucala depends on your individual needs, treatment response, and your doctor’s ...

Treatment with Nucala, an interleukin-5 antagonist monoclonal antibody, significantly reduced exacerbations leading to hospitalizations and emergency department visits. The Food and Drug ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. Why am I being given NUCALA? NUCALA contains the active ingredient ...

Nucala (mepolizumab) can cause side effects that range from mild to serious. More common side effects include headache and back pain. If side effects from Nucala become difficult to tolerate, talk ...

Nucala isn’t known to interact with other medications, supplements, herbs, vitamins, or food. However, interactions may be recognized in the future. Certain vaccines, including cholera and COVID-19 ...

GUANGZHOU, China--(BUSINESS WIRE)--Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage biopharmaceutical company, today announced that dosing has begun in a Phase I clinical study to compare ...

(RTTNews) - GlaxoSmithKline plc (GSK.L, GSK) announced Friday that the US Food and Drug Administration has approved two new methods for administering Nucala (mepolizumab), an autoinjector and a ...